Early Cancer Detection Startup GRAIL Closes on $900 Million in Series B Funding
In March 2017, life sciences startup GRAIL announced that it had raised $900 million in Series B funding. The newly acquired investment capital puts GRAIL one step closer toward its goal of developing a blood test that can detect early signs of cancer. Founded in 2016 by genomics company Illumina, GRAIL uses top-of-the-line DNA sequencing machinery to uncover early, free-floating cancer in the bloodstream. If caught during this early stage, its possible that the disease can be treated before it takes hold in the body. But it...